


## IngenOx Therapeutics Chief Medical Officer Meets Chinese Premier to Advance International Anti-Cancer Cooperation

**Oxford, UK - 10th February 2025** – **IngenOx Therapeutics**, the Oxford-based biopharmaceutical company, announced that its Chief Medical Officer, Professor David Kerr CBE, met with Chinese Premier Li Qiang on 26 January 2025 at an international symposium held at the Great Hall of the People in Beijing. The discussion focused on new initiatives to tackle the global socio-economic burden of cancer.

Professor Kerr, who received the 2024 Chinese Government Friendship Award, was joined by a distinguished panel of international experts from various fields to explore how technological innovation can deliver tangible benefits for people worldwide.



**Professor David Kerr and Premier Li Qiang at the Great Hall of the People, Beijing**

During his presentation, Professor Kerr highlighted the significant progress already achieved through UK-China academic partnerships in cancer prevention, research, and treatment. A key example is the Sichuan University (West China Hospital)-Oxford University Gastrointestinal Cancer Centre (<https://www.cancer.ox.ac.uk/research/networks/west-china-hospital>), which is dedicated to developing and implementing effective cancer control strategies. To further build on these advancements, Professor Kerr proposed the establishment of a "China-UK Cancer Prevention and Control Alliance." This initiative would bring together leading healthcare, research, and policy experts from both nations to share best practices, develop innovative cancer control models, and drive major breakthroughs in cancer prevention, treatment, and healthcare systems.

**David Kerr, CMO of IngenOx Therapeutics and Professor of Cancer Medicine at the University of Oxford**, commented: *"It was a great honour to be asked to participate in this symposium led by Premier Li. I firmly believe that international collaboration, bringing together some of the greatest cancer scientists and clinicians in the world, is the optimal way for the UK and China to cooperate to best serve the community of cancer patients we represent."*

**Nick La Thangue, CEO of IngenOx Therapeutics and Professor of Cancer Biology at the University of Oxford**, commented: *"We are excited about David's proposals to initiate new partnerships with world renowned cancer centres. IngenOx is ideally positioned to assist in achieving these important objectives"*

## NOTES:

### About David Kerr

**Professor David Kerr CBE MD DSc FRCP FRGCP FACP FESMO FMedSci** is a British medical oncologist with over 40 years of experience in cancer research. His primary interest is the treatment and management of bowel cancer. He is currently Professor of Cancer Medicine at the University of Oxford and holds additional positions as Honorary Consultant Medical Oncologist at the Oxford Cancer Centre, Co-Director of the Oxford-Sichuan Gastrointestinal Cancer Centre, and Honorary Professor at the University of Oslo. In the business field, David has co-founded several companies, including Cobra Therapeutics, Oxford Cancer Biomarkers, Celleron Therapeutics, SynOx Therapeutics, and IngenOx Therapeutics.

### About IngenOx Therapeutics

is a biopharmaceutical company focused on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours. It is a spinout from the University of Oxford and is located in the Oxford Science Park, UK. Its pipeline comprises early to late-stage products that work in different ways to activate the immune response against cold tumours, which are generally poorly recognised by the immune system. An exciting proprietary platform technology focuses on precision cancer vaccines that act by targeting the immune response to a novel source of cancer antigens.

The company has secured multiple rounds of investment and has numerous license and partnership agreements in place.

For more information see [www.ingenox.com](http://www.ingenox.com)